Mild cognitive impairment and Alzheimer's disease contribute to cognitive decline in the aging population, affecting 10–20% of adults ≥60 years and 50 million individuals globally, respectively. Chronic inflammation is implicated in their pathogenesis, but relationships remain unclear. This study examined longitudinal associations between inflammatory biomarkers and cognition in 4228 English Longitudinal Study of Aging participants over two- and ten-year follow-ups. Mixed-effects models evaluated C-reactive protein, ferritin, fibrinogen, and white blood cell count in relation to memory, executive function, processing speed, and overall cognition. The results indicated cumulative inflammation-related cognitive decline in adults aged ≥75 years.
SongWXWuWWZhaoYY, et al.Evidence from a meta-analysis and systematic review reveals the global prevalence of mild cognitive impairment. Front Aging Neurosci2023; 15: 1227112.
2.
BaiWChenPCaiH, et al.Worldwide prevalence of mild cognitive impairment among community dwellers aged 50 years and older: a meta-analysis and systematic review of epidemiology studies. Age Ageing2022; 51: afac173.
3.
SalariNLotfiFAbdolmalekiA, et al.The global prevalence of mild cognitive impairment in geriatric population with emphasis on influential factors: a systematic review and meta-analysis. BMC Geriatr2025; 25: 313.
LinC-HLinELaneH-Y. Genetic biomarkers on age-related cognitive decline. Front Psychiatry2017; 8: 247.
6.
MekhoraCLamportDJSpencerJPE. An overview of the relationship between inflammation and cognitive function in humans, molecular pathways and the impact of nutraceuticals. Neurochem Int2024; 181: 105900.
7.
PietrzakRHLimYYNeumeisterA, et al.Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study. JAMA Psychiatry2015; 72: 284–291.
8.
ZhangJZhangYWangJ, et al.Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther2024; 9: 211.
9.
RajanKBWeuveJBarnesLL, et al.Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060). Alzheimers Dement2021; 17: 1966–1975.
10.
WilsonRSLeurgansSEBoylePA, et al.Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch Neurol2011; 68: 351–356.
11.
KoyamaAO'BrienJWeuveJ, et al.The role of peripheral inflammatory markers in dementia and Alzheimer's disease: a meta-analysis. J Gerontol A Biol Sci Med Sci2013; 68: 433–440.
12.
XuGZhangHZhangS, et al.Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int J Clin Pract2008; 62: 1070–1075.
13.
DarweeshSKLWoltersFJIkramMA, et al.Inflammatory markers and the risk of dementia and Alzheimer's disease: a meta-analysis. Alzheimers Dement2018; 14: 1450–1459.
14.
AytonSFauxNGBushAI. Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nat Commun2015; 6: 6760.
15.
JanowitzDHabesMToledoJB, et al.Inflammatory markers and imaging patterns of advanced brain aging in the general population. Brain Imaging Behav2020; 14: 1108–1117.
16.
Singh-ManouxADugravotABrunnerE, et al.Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife. Neurology2014; 83: 486–493.
17.
AlleyDECrimminsEMKarlamanglaA, et al.Inflammation and rate of cognitive change in high-functioning older adults. J Gerontol A Biol Sci Med Sci2008; 63: 50–55.
18.
WangYFuJLiangF, et al.High-sensitivity C-reactive protein, its change, and cognitive function: a national population-based cohort study. Brain Sci2023; 13: 413.
19.
ZhengFXieW. High-sensitivity C-reactive protein and cognitive decline: the English longitudinal study of ageing. Psychol Med2018; 48: 1381–1389.
20.
PyunJMRyooNParkYH, et al.Fibrinogen levels and cognitive profile differences in patients with mild cognitive impairment. Dement Geriatr Cogn Disord2020; 49: 489–496.
21.
LuoJThomassenJQNordestgaardBG, et al.Blood leukocyte counts in Alzheimer disease. JAMA Netw Open2022; 5: e2235648.
22.
AytonSFauxNGBushAI. Association of cerebrospinal fluid ferritin level with preclinical cognitive decline in APOE-ε4 carriers. JAMA Neurol2017; 74: 122–125.
23.
GongZSongWGuM, et al.Association between serum iron concentrations and cognitive impairment in older adults aged 60 years and older: a dose-response analysis of national health and nutrition examination survey. PLoS One2021; 16: e0255595.
24.
SteptoeABreezeEBanksJ, et al.Cohort profile: the English longitudinal study of ageing. Int J Epidemiol2013; 42: 1640–1648.
CadarDAbellJMatthewsFE, et al.Cohort profile update: the harmonised cognitive assessment protocol sub-study of the English longitudinal study of ageing (ELSA-HCAP). Int J Epidemiol2021; 50: 725–726i.
27.
McCreaSMRobinsonTP. Visual puzzles, figure weights, and cancellation: some preliminary hypotheses on the functional and neural substrates of these three new WAIS-IV subtests. Int Scholarly Res Notices2011; 2011: 123173.
28.
LivingstonGHuntleyJLiuKY, et al.Dementia prevention, intervention, and care: 2024 report of the Lancet standing commission. Lancet2024; 404: 572–628.
29.
YuRKongSDIrelandC, et al.Associations of high-sensitivity C-reactive protein with neuropsychological outcomes and cerebral white matter hyperintensities in older adults at risk of dementia. Brain Behav Immun Health2025; 43: 100924.
30.
SalamiAPapenbergGSitnikovR, et al.Elevated neuroinflammation contributes to the deleterious impact of iron overload on brain function in aging. Neuroimage2021; 230: 117792.
31.
MerliniMRafalskiVARios CoronadoPE, et al.Fibrinogen induces microglia-mediated spine elimination and cognitive impairment in an Alzheimer's disease model. Neuron2019; 101: 1099–1108.
32.
PyunJMRyooNParkYH, et al.Fibrinogen levels and cognitive profile differences in patients with mild cognitive impairment. Dement Geriatr Cogn Disord2021; 49: 489–496.
33.
BettcherBMWilheimRRigbyT, et al.C-reactive protein is related to memory and medial temporal brain volume in older adults. Brain Behav Immun2012; 26: 103–108.
34.
PavuluriKHustonJEhmanRL, et al.Brain mechanical properties predict longitudinal cognitive change in aging and Alzheimer's disease. Neurobiol Aging2025; 147: 203–212.
35.
BahorikALHoangTDJacobsDR, et al.Association of changes in C-reactive protein level trajectories through early adulthood with cognitive function at midlife: the CARDIA study. Neurology2024; 103: e209526.
36.
PetersenMARyuJKAkassoglouK. Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. Nat Rev Neurosci2018; 19: 283–301.
37.
BeydounMADoreGACanasJ-A, et al.Systemic inflammation is associated with longitudinal changes in cognitive performance among urban adults. Front Aging Neurosci2018; 10: 313.
38.
ZhouZLiangYZhangX, et al.Fibrinogen and risk of dementia: a systematic review and meta-analysis. Neurosci Biobehav Rev2020; 112: 353–360.
39.
HarringtonLBEhlertANThackerEL, et al.Hemostatic factor levels and cognitive decline in older adults: the cardiovascular health study. J Thromb Haemost2021; 19: 1219–1227.
40.
AretzBDoblhammerGHenekaMT. The role of leukocytes in cognitive impairment due to long-term exposure to fine particulate matter: a large population-based mediation analysis. Alzheimers Dement2024; 20: 8715–8727.
41.
KillipSBennettJMChambersMD. Iron deficiency anemia. Am Fam Physician2007; 75: 671–678.
42.
PengJLiuBTanW, et al.Association between body iron status and cognitive task performance in a nationally representative sample of older adults. Aging Dis2024; 16: 1141–1148.
43.
Rosell-DíazMSantos-GonzálezEMotger-AlbertíA, et al.Lower serum ferritin levels are associated with worse cognitive performance in aging. J Nutr Health Aging2024; 28: 100190.
44.
WalkerKAGottesmanRFWuA, et al.Systemic inflammation during midlife and cognitive change over 20 years: the ARIC study. Neurology2019; 92: e1256–e1267.
45.
KellnerAMatschkeJBernreutherC, et al.Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol2009; 65: 24–31.
46.
YaffeKKanayaALindquistK, et al.The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA2004; 292: 2237–2242.
47.
KomulainenPLakkaTAKivipeltoM, et al.Serum high sensitivity C-reactive protein and cognitive function in elderly women. Age Ageing2007; 36: 443–448.
48.
KatselPTanWHaroutunianV. Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals. PLoS One2009; 4: e7642.
49.
ArakelyanNAKupriyanovaDAVasilevskaJ, et al.Sexual dimorphism in immunity and longevity among the oldest old. Front Immunol2025; 16: 1525948.
50.
SachdevPSBlackerDBlazerDG, et al.Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol2014; 10: 634–642.
51.
BelaidiAABushAIAytonS. Apolipoprotein E in Alzheimer’s disease: molecular insights and therapeutic opportunities. Mol Neurodegener2025; 20: 47.
52.
LiFLiuYLuL, et al.Rich-club reorganization of functional brain networks in acute mild traumatic brain injury with cognitive impairment. Quant Imaging Med Surg2022; 12: 3932–3946.
53.
Delgado-SaboritJMGuercioVGowersAM, et al.A critical review of the epidemiological evidence of effects of air pollution on dementia, cognitive function and cognitive decline in adult population. Sci Total Environ2021; 757: 143734.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
